Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1662-1670

  Montgomery, Justin I ^a   Brown, Matthew F ^a   Reilly, Usa ^a   Price, Loren M ^a   Abramite, Joseph A ^a   Arcari, Joel ^a   Barham, Rose ^a   Che, Ye ^a   Chen, Jinshan Michael ^a   Chung, Seung Won ^a   Collantes, Elizabeth M ^a   Desbonnet, Charlene ^a   Doroski, Matthew ^a   Doty, Jonathan ^a   Engtrakul, Juntyma J ^a   Harris, Thomas M ^a   Huband, Michael ^a   Knafels, John D ^a   Leach, Karen L ^a   Liu, Shenping ^a   Marfat, Anthony ^a   McAllister, Laura ^a   McElroy, Eric ^a   Menard, Carol A ^a   Mitton Fry, Mark ^a   Mullins, Lisa ^a   Noe, Mark C ^a   O'Donnell, John ^a   Oliver, Robert ^a   Penzien, Joseph ^a   Plummer, Mark ^a   Shanmugasundaram, Veerabahu ^a   Thoma, Christy ^a   Tomaras, Andrew P ^a   Uccello, Daniel P ^a   Vaz, Alfin ^a   Wishka, Donn G ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PYRIDONE METHYLSULFONE HYDROXAMATE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CRYSTAL STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE INFECTION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PSEUDOMONAS AERUGINOSA; PYRIDONES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS;

EID: 84863119192     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2014875     Document Type: Article

References (31)

1. Cooper, M. A.; Shlaes, D. Fix the antibiotics pipeline Nature 2011, 472, 32
2. Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE J. Infect. Dis. 2008, 197 (8) 1079-1081 (Pubitemid 351590040)
3. Rice, L. B. Progress and challenges in implementing the research on ESKAPE pathogens Infect. Control Hosp. Epidemiol. 2010, 31 (Suppl 1) S7-S10
4. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48 (1) 1-12
5. Barb, A. W.; Zhou, P. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis Curr. Pharm. Biotechnol. 2008, 9 (1) 9-15 (Pubitemid 351266965)
6. Pitout, J. D.; Laupland, K. B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public health concern Lancet Infect. Dis. 2008, 8 (3) 159-166 (Pubitemid 351249250)
7. Nordmann, P.; Cuzon, G.; Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria Lancet Infect. Dis. 2009, 9 (4) 228-236
8. Sidjabat, H.; Nimmo, G. R.; Walsh, T. R.; Binotto, E.; Htin, A.; Hayashi, Y.; Li, J.; Nation, R. L.; George, N.; Paterson, D. L. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-beta-lactamase Clin. Infect. Dis. 2011, 52 (4) 481-484
9. Onishi, H. R.; Pelak, B. A.; Gerckens, L. S.; Silver, L. L.; Kahan, F. M.; Chen, M. H.; Patchett, A. A.; Galloway, S. M.; Hyland, S. A.; Anderson, M. S.; Raetz, C. R. Antibacterial agents that inhibit lipid A biosynthesis Science 1996, 274 (5289) 980-982 (Pubitemid 26398419)
10. Jackman, J. E.; Fierke, C. A.; Tumey, L. N.; Pirrung, M.; Uchiyama, T.; Tahir, S. H.; Hindsgaul, O.; Raetz, C. R. H. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria: inhibition of diverse UDP-3- O -(R -3-hydroxymyristoyl)- N -acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs J. Biol. Chem. 2000, 275 (15) 11002-11009 (Pubitemid 30212739)
11. Clements, J. M.; Coignard, F.; Johnson, I.; Chandler, S.; Palan, S.; Waller, A.; Wijkmans, J.; Hunter, M. G. Antibacterial activities and characterization of novel inhibitors of LpxC Antimicrob. Agents Chemother. 2002, 46 (6) 1793-1799 (Pubitemid 34535199)
12. Kline, T.; Andersen, N. H.; Harwood, E. A.; Bowman, J.; Malanda, A.; Endsley, S.; Erwin, A. L.; Doyle, M.; Fong, S.; Harris, A. L.; Mendelsohn, B.; Mdluli, K.; Raetz, C. R. H.; Stover, C. K.; Witte, P. R.; Yabannavar, A.; Zhu, S. Potent, Novel in Vitro Inhibitors of the Pseudomonas aeruginosa Deacetylase LpxC J. Med. Chem. 2002, 45 (14) 3112-3129 (Pubitemid 34721533)
13. Pirrung, M. C.; Tumey, L. N.; Raetz, C. R. H.; Jackman, J. E.; Snehalatha, K.; McClerren, A. L.; Fierke, C. A.; Gantt, S. L.; Rusche, K. M. Inhibition of the Antibacterial Target UDP-(3- O -acyl)- N -acetylglucosamine Deacetylase (LpxC): Isoxazoline Zinc Amidase Inhibitors Bearing Diverse Metal Binding Groups J. Med. Chem. 2002, 45 (19) 4359-4370 (Pubitemid 35025582)
14. Anderson, N. H.; Bowman, J.; Erwin, A.; Harwood, E.; Kline, T.; Mdluli, K.; Ng, S.; Pfister, K. B.; Shawar, R.; Wagman, A.; Yabannavar, A. Preparation of amino acid derivatives as antibacterial agents. WO 2004062601, 2004
15. McClerren, A. L.; Endsley, S.; Bowman, J. L.; Andersen, N. H.; Guan, Z.; Rudolph, J.; Raetz, C. R. H. A Slow, Tight-Binding Inhibitor of the Zinc-Dependent Deacetylase LpxC of Lipid A Biosynthesis with Antibiotic Activity Comparable to Ciprofloxacin Biochemistry (Moscow) 2005, 44 (50) 16574-16583 (Pubitemid 41832039)
16. Shin, H.; Gennadios, H. A.; Whittington, D. A.; Christianson, D. W. Amphipathic benzoic acid derivatives: synthesis and binding in the hydrophobic tunnel of the zinc deacetylase LpxC Bioorg. Med. Chem. 2007, 15 (7) 2617-2623 (Pubitemid 46367709)
17. Mansoor, U. F.; Reddy, P. A. P.; Siddiqui, M. A. Preparation of methylhydantoin derivatives for use as antimicrobial agents. WO 2008027466, 2008
18. Takashima, H.; Yoshinaga, M.; Ushiki, Y.; Tsuruta, R.; Urabe, H.; Tanikawa, T.; Tanabe, K.; Baba, Y.; Yokotani, M.; Kawaguchi, Y.; Kotsubo, H.; Tsutsui, Y. Preparation of quinoline-4-carbohydroxamic acid and naphthyridine-4-carbohydroxamic acid derivatives as antibacterial agents. WO 2008105515, 2008
19. Barb, A. W.; Leavy, T. M.; Robins, L. I.; Guan, Z.; Six, D. A.; Zhou, P.; Bertozzi, C. R.; Raetz, C. R. H. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC Biochemistry (Moscow) 2009, 48 (14) 3068-3077
20. Reddy, P. A. P.; Mansoor, U. F.; Siddiqui, M. A. Preparation of heterocyclic compounds as LpxC inhibitors for use as antibacterial agents. WO 2009158369, 2009
21. Benenato, K. E.; Choy, A. L.; Hale, M. R.; Hill, P.; Marone, V.; Miller, M. Preparation of hydroxamic acid derivatives as Gram-negative antibacterial agents. WO 2010100475, 2010
22. Mansoor, U. F.; Reddy, P. A.; Siddiqui, M. A. Preparation of urea derivatives as antibacterial agents for treatment of diseases mediated by LpxC. WO 2010017060, 2010
23. Takashima, H.; Suga, Y.; Urabe, H.; Tsuruta, R.; Kotsubo, H.; Oohori, R.; Kawaguchi, Y. Preparation of N -hydroxy-naphthyridinecarboxamides as LpxC inhibitors and antibacterial agents. WO 2010024356, 2010
24. Liang, X.; Lee, C.-J.; Chen, X.; Chung, H. S.; Zeng, D.; Raetz, C. R. H.; Li, Y.; Zhou, P.; Toone, E. J. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold Bioorg. Med. Chem. 2011, 19 (2) 852-860
25. Mansoor, U. F.; Vitharana, D.; Reddy Panduranga, A.; Daubaras Dayna, L.; McNicholas, P.; Orth, P.; Black, T.; Siddiqui, M. A. Design and synthesis of potent Gram-negative specific LpxC inhibitors Bioorg. Med. Chem. Lett. 2011, 21 (4) 1155-1161
26. Brown, M. F.; Reilly, U.; Abramite, J. A.; Arcari, J. T.; Oliver, R.; Barham, R. A.; Che, Y.; Chen, J. M.; Collantes, E. M.; Chung, S. W.; Desbonnet, C; Doty, J.; Doroski, M; Engtrakul, J. J.; Harris, T. M.; Huband, M.; Knafels, J.; Leach, K. L.; Liu, S.; Marfat, A.; Marra, A; McElroy, E.; Melnick, M.; Menard, C. A.; Montgomery, J. I.; Mullins, L.; Noe, M. C.; O'Donnell, J.; Penzien, J.; Plummer, M. S.; Price, L. M.; Shanmugasundaram, V.; Thoma, C.; Uccello, D.; Warmus, J.; Wishka, D. G. Potent inhibitors of LpxC for the treatment of gram-negative infections J. Med. Chem. 2012, 55, 914-923
27. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nature Rev. Drug Discovery 2010, 9 (12) 929-939
28. Benet, L. Z.; Hoener, B. A. Changes in plasma protein binding have little clinical relevance Clin. Pharmacol. Ther. 2002, 71 (3) 115-121 (Pubitemid 34271114)
29. Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. W.; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure J. Med. Chem. 2006, 49 (23) 6672-6682 (Pubitemid 44749735)
30. Langsdorf, E. F.; Malikzay, A.; Lamarr, W. A.; Daubaras, D.; Kravec, C.; Zhang, R.; Hart, R.; Monsma, F.; Black, T.; Ozbal, C. C.; Miesel, L.; Lunn, C. A. Screening for antibacterial inhibitors of the UDP-3- O -(R -3-hydroxymyristoyl)- N -acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay J. Biomol. Screening 2010, 15 (1) 52-61
31. Mochalkin, I.; Knafels, J. D.; Lightle, S. Crystal Structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor Protein Sci. 2008, 17, 450-457 (Pubitemid 351281545)